FERROSA raises USD 3.5 M

FERROSA, founded in Basel in 2026 by Forty51 Ventures, is developing a bispecific antibody against inflammatory anaemia. It has raised USD 3.5 million in seed funding to take its preclinical programme through to in vivo proof of concept.

Announced on
Round
Seed
Amount
USD 3.5 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic